Symptoms and General Pathology

All Conditions

Substance Related Disorders

Behaviors and Mental Disorders

Nervous System Diseases

Constipation

Cancer Pain

Pain

Opioid-Induced Constipation

Signs and Symptoms, Digestive

Neurologic Manifestations

Narcotic-Related Disorders

Substance-Related Disorders

Chemically-Induced Disorders

Mental Disorders

Psychotic Disorders

Narcotic Antagonists

All Drugs and Chemicals

Analgesics

Central Nervous System Depressants

Naloxone

Analgesics, Opioid

Naloxegol

Narcotics

Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone

Andrew Davies, MD

Jan Tack, MD

This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical practice. Subjects who are receiving Naloxegol (prescribed by their physician according to the SmPC, which recommends that all currently used maintenance laxative therapy should be halted) during the enrolment period may be eligible for enrolment into the study.

The objective of this study is to assess the safety and efficacy of Naloxegol in a real world setting in cancer patients.

The primary safety end point is the incidence of adverse events leading to study discontinuation.

The primary efficacy end point is the response rate assessed in the 4 week observation period. Response is defined as three or more bowel movements (without the use of rescue laxative treatment in the previous 24 hours) per week and an increase of one or more bowel movements over baseline.

Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.

Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With Opioid Induced Constipation.

Bowel Function Index (BFI) score change of ≥12 points

Patient Global Impression of Improvement (PGI-I)

Apices Soluciones S.L.

Kyowa Kirin Pharmaceutical Development Ltd

Naloxegol 25mg tablets once daily for two weeks

Naloxegol 25mg tablets for two weeks, followed by a two week open-label period

Placebo once daily for two weeks, followed by two week open-label period

Placebo

Janet Bull, MD

The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of a two week randomized double blind period followed by a two week open-label period.

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation

Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.

Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.

Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.

Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.

Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.

Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.

Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.

The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.

Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.

The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.

The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.

Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.

The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.

The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.

Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.

Degree of straining scale is 1 to 5 with 1 being "not at all" and 5 being "an extreme amount". Lower scores are better and higher scores are worse.

Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.

Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.

AstraZeneca

Hospice of Henderson County, Inc.

Chief Medical Officer

Placebo once daily for two weeks

Placebo: Placebo once daily for two weeks, followed by two week open-label period

Naloxegol 25mg tablets once daily for two weeks

Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period

Total

Age, Categorical

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

Baseline Numerical Rating Scale (NRS) for Pain during the OIC Confirmation Period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome.

Baseline Numerical Rating Scale (NRS) for Pain

Baseline Electrocardiogram QTC Interval

Baseline Electrocardiogram Heart Rate

Baseline Daily Opioid Use

Baseline Systolic Blood Pressure

Baseline Diastolic Blood Pressure

Baseline Pulse Rate

The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.

Baseline Bristol Stool Scale score

Baseline Respiratory Rate

Degree of straining scale measures the amount of straining during a bowel movement. The scale is 1 to 5 with 1 being "not at all" and 5 being "an extreme amount". Lower scores are better and higher scores are worse.

Baseline Degree of Straining

Baseline Complete Evacuation with Bowel Movements

Abdominal symptoms

Rectal Symptoms

Stool symptoms

Total Score

The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.

The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.

Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)

Physical Discomfort

Psychosocial discomfort

Worries/concerns

Satisfaction

The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Each item is scored 0-4. Items 1-4 measure physical discomfort (total subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.

The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.

Baseline Patient Assessment of Constipation (PAC-QOL)

Due to significant recruitment challenges enrollment was stopped. Only 5 patients were randomized (less than 12% of expected). There was insufficient data to perform the protocol specified analysis.

Numerical Rating Scale (NRS) for Pain Change From Baseline

Daily Opioid Use Change From Baseline

All abnormal lab values were deemed not clinically significant by Investigators. Therefore, changes did not meet the criteria for an adverse event and changes were not collected.

Adverse Events Associated With Blood Laboratory Result Changes From Baseline

Electrocardiogram QTC Interval

Electrocardiogram Heart Rate

Change From Baseline in Systolic Blood Pressure

Change From Baseline in Diastolic Blood Pressure

Change From Baseline in Respiratory Rate

Change From Baseline in Pulse Rate

Rescue Free Bowel Movements (RFBM) Responder Rate

Time to First Post-dose Rescue Free Laxation

Bristol Stool Scale (BSS) Score

Abdominal Symptoms

Stool Symptoms

Patient Assessment of Constipation Symptoms (PAC-SYM)

Physical discomfort

Psychosocial Discomfort

Patient Assessment of Constipation Quality of Life (PAC-QOL)

Degree of Straining Question With Each Bowel Movement

Complete Evacuation Question With Each Bowel Movement

Randomization Period

Open-Label Period

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

Laboratory Biomarker Analysis

Quality-of-Life Assessment

Pankaj Gupta, MD

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

PRIMARY OBJECTIVES:

I. To determine feasibility and safety of long-term administration of two doses of a peripheral opioid receptor antagonist in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line systemic therapy.

SECONDARY OBJECTIVES:

I. To explore whether patients randomized to one or both of the two study drug arms have less decline in health-related quality of life (HRQoL) than patients randomized to placebo.

II. To estimate the difference in the pain levels and opioid/non-opioid analgesic requirements between patients receiving naloxegol or placebo.

III. To estimate the difference in the adverse peripheral effects of opioids (e.g. constipation, nausea/emesis, dry mouth and urinary retention) between patients receiving naloxegol or placebo.

IV. To explore whether there is a signal that naloxegol may be associated with longer progression-free survival (PFS) and overall survival (OS).

V. To evaluate the difference in discontinuation rate of systemic therapy due to adverse events (AEs) and deaths attributable to systemic therapy.

After completion of study treatment, patients are followed up every 3 months.

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer

Calculated as the total number of patients accrued to the study over two years divided by 184, the total expected accrual of patients evaluable for the primary endpoint.

The proportion of patients alive at 6 months who continue study drug and complete the health-related quality of life and other forms for at least 6 months will be calculated by arm.

The frequency of adverse events will be summarized by arm and compared between each treatment arm vs the placebo arm using Fisher's exact test. \<3 is better and 3+ is worse.

Health-related quality of life scores at each timepoint and changes in scores between 6 months and baseline will be summarized by mean standard deviation, median (inter-quartile range). Scores will be plotted to explore the pattern over time and to examine differences between treatment arms. Differences in health-related quality of life between the treatment arms and the placebo arm will be conducted through linear mixed models and growth curve models to account for repeated assessments. Trial outcome index score is 0-92 with 0 being the worst and 92 being the best.

Health-related quality of life scores at each timepoint and changes in scores between 6 months and baseline will be summarized by mean standard deviation, median (inter-quartile range). Scores will be plotted to explore the pattern over time and to examine differences between treatment arms. Differences in health-related quality of life between the treatment arms and the placebo arm will be conducted through linear mixed models and growth curve models to account for repeated assessments. Function subscales score is 0-28 with 0 being the worst and 28 being the best.

Health-related quality of life scores at each timepoint and changes in scores between 6 months and baseline will be summarized by mean standard deviation, median (inter-quartile range). Scores will be plotted to explore the pattern over time and to examine differences between treatment arms. Differences in health-related quality of life between the treatment arms and the placebo arm will be conducted through linear mixed models and growth curve models to account for repeated assessments. Lung cancer subscale score is 0-36 with 0 being the worst and 36 being the best.

Patient-Reported Outcome-Common Terminology Criteria for Adverse Events items will be summarized by arm. Patient-Reported Outcome-Common Terminology Criteria for Adverse Events response will be compared between the treatment arms vs. placebo arm using a chi-square test or Fisher's exact test as appropriate. Chosen PRO-CTCAE question is "In the last 7 days, what was the SEVERITY of your PAIN IN THE ABDOMEN (BELLY AREA) at its WORST?"

Linear Analogue Self-Assessment items will be summarized by arm. Linear Analogue Self-Assessment scores will be compared between treatment arms versus placebo arm using Wilcoxon test. Linear Analogue Self-Assessment score is 0-10, with 0 being no trouble with ability to urinate easily and 10 being worst trouble with ability to urinate easily.

Opioid-induced constipation rating scale will be summarized by arm. Scores will be compared between treatment arms vs. placebo arm using Wilcoxon test. Question from Bowel Function Diary is "In the past 24 hours, how much pain did you feel in your abdomen because of constipation?". Opioid-induced constipation rating scale is from 0-6, with 0 being none and 6 being very severe.

Pain scores will be summarized by arm. Pain scores will be compared between treatment arms vs. placebo using Wilcoxon test. Pain score scale is 0-10, with 10 being worst pain imaginable

The protocol-defined analysis for this secondary endpoint was not performed due to not specifying analgesic use in the questionnaire. Analgesic use will be summarized by arm. Frequencies of analgesic used will be compared using chi-square test or Fisher's exact test, as appropriate.

A Fisher's exact test was not performed due to low sample size. Frequency of discontinuation of chemotherapy will be summarized by arm and compared between each treatment arm vs the placebo arm using Fisher's exact test.

Progression-free survival probabilities will be estimated by arm using the Kaplan-Meier estimator. In an exploratory manner, a Cox proportional hazards model will be used to determine the effect of naloxegol on progression-free survival.

Overall survival probabilities will be estimated by arm using the Kaplan-Meier estimator. In an exploratory manner, a Cox proportional hazards model will be used to determine the effect of naloxegol on overall survival.

The protocol-defined analysis for this secondary endpoint was not performed due to being a correlative endpoint and not being collected in the data. MOR expression and activation will be included as a covariate in the linear mixed model, an interaction between MOR expression/activation and treatment will be evaluated.

National Cancer Institute (NCI)

Alliance for Clinical Trials in Oncology

For Group I (Lower Dose Naloxegol, Placebo), 2 patients withdrew prior to starting treatment and no AE data was collected.

For Group III (Placebo), 3 patients withdrew prior to starting treatment and no AE data was collected.

Quality-of-Life Assessment: Ancillary studies

Group III (Placebo)

Group II (Placebo, Higher Dose Naloxegol)

Group I (Lower Dose Naloxegol, Placebo)

Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\>\> \>\> Naloxegol: Given PO\>\>

\>\> Placebo: Given PO\>\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>\>

\>\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\>\> \>\> Naloxegol: Given PO\>\>

\>\> Placebo: Given PO\>\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>\>

\>\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\>\>

\>\> Placebo: Given PO\>\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>\>

\>\> Quality-of-Life Assessment: Ancillary studies

Age, Continuous

Ethnicity (NIH/OMB)

Planned use of Bevacizumab

Measure Description: ECOG = 0: Fully active, able to carry on all pre-disease performance without restriction.

ECOG = 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.

ECOG = 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours.

ECOG = 0 is better. ECOG = 2 is worse.

ECOG Performance Score

Tx: Main tumor cannot be measured.

T0: There is no evidence of a primary tumor.

T1-T4 describe the size and location of the tumor. A larger tumor or a tumor that has grown deeper into nearby tissue will get a higher number and letter.

From best to worst, T0, T1a, T1b, T2a, T2b, T3a, T3b, T4.

Pathologic T Stage

Current smoker

Former smoker (no smoking for one year or more)

Never smoked (less than 100 cigarettes in lifetime)

Smoking Status

Dr. Pankaj Gupta

Expected accrued patients to be evaluable

Expected Accrued Patients

Observed Accrual Rate Defined as Rate of Accrual Remaining >= 80% of the Expected

Proportion of Patients Alive Who Continue Study Drug and Complete the Health-related Quality of Life and Other Forms

Comparison of Hematologic 3+ vs Hematologic \<3

Comparison of Non-Hematologic 3+ vs Non-Hematologic \<3

Hematologic Adverse Events (regardless of attribution) : 3+

Hematologic Adverse Events (regardless of attribution) : <3

Non-Hematologic Adverse Events (regardless of attribution) : 3+

Non-Hematologic Adverse Events (regardless of attribution) : <3

Hematologic Adverse Events (at least possibly related to study) : 3+

Hematologic Adverse Events (at least possibly related to study) : <3

Non-Hematologic Adverse Events (at least possibly related to study) : 3+

Non-Hematologic Adverse Events (at least possibly related to study) : <3

Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\> \>\>

\>

\>\> Naloxegol: Given PO\>

\>\>

\>

\>\> Placebo: Given PO\>

\>\>

\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>

\>\>

\>

\>\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\> \>\>

\>

\>\> Naloxegol: Given PO\>

\>\>

\>

\>\> Placebo: Given PO\>

\>\>

\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>

\>\>

\>

\>\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.\>

\>\>

\>

\>\> Placebo: Given PO\>

\>\>

\>

\>\> Laboratory Biomarker Analysis: Correlative studies\>

\>\>

\>

\>\> Quality-of-Life Assessment: Ancillary studies

Incidence of Adverse Events as Described and Graded by the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0

Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

\>

\>

\>

\>

\>

\> Naloxegol: Given PO

\>

\>

\>

\>

\>

\> Placebo: Given PO

\>

\>

\>

\>

\>

\> Laboratory Biomarker Analysis: Correlative studies

\>

\>

\>

\>

\>

\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

\>

\>

\>

\>

\>

\> Naloxegol: Given PO

\>

\>

\>

\>

\>

\> Placebo: Given PO

\>

\>

\>

\>

\>

\> Laboratory Biomarker Analysis: Correlative studies

\>

\>

\>

\>

\>

\> Quality-of-Life Assessment: Ancillary studies

Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.

\>

\>

\>

\>

\>

\> Placebo: Given PO

\>

\>

\>

\>

\>

\> Laboratory Biomarker Analysis: Correlative studies

\>

\>

\>

\>

\>

\> Quality-of-Life Assessment: Ancillary studies

Change in Trial Outcome Index

Physical Well Being

Two patients on the Naloxegol 12.5 mg arm did not complete all of the questions for the Fact-L at 6 months.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.	NCT03638440	Opioid Induced ...	Naloxegol	18 Years -	Kyowa Kirin Pharmaceutical Development Ltd
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)	NCT02839889	Cancer Constipation Pain	Naloxegol Placebo	18 Years -	Hospice of Henderson County, Inc.
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer	NCT03087708	Stage IIIB Non-... Stage IV Non-sm...	Naloxegol Placebo Laboratory Biom... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol	NCT04294550	Opioid Use Constipation Dr... Cancer	Naloxegol	18 Years -	Fondazione ANT Italia ONLUS
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.	NCT03638440	Opioid Induced ...	Naloxegol	18 Years -	Kyowa Kirin Pharmaceutical Development Ltd
Naloxegol in Cancer Opioid-Induced Constipation	NCT02745353	Constipation	naloxegol	18 Years -	University of California, San Diego
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol	NCT04294550	Opioid Use Constipation Dr... Cancer	Naloxegol	18 Years -	Fondazione ANT Italia ONLUS
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.	NCT03638440	Opioid Induced ...	Naloxegol	18 Years -	Kyowa Kirin Pharmaceutical Development Ltd
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)	NCT02839889	Cancer Constipation Pain	Naloxegol Placebo	18 Years -	Hospice of Henderson County, Inc.

Spots Global Cancer Trial Database for naloxegol

Every month we try and update this database with for naloxegol cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for naloxegol

Every month we try and update this database with for naloxegol cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for naloxegol cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.